Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer (EOC) or primary peritoneal cancer (PPC): a Gynecologic Oncology Group (GOG) study. - Burger,R.A.; Sill,M.; Monk,B.J.; Greer,B.; Sorosky,J. (Proc Am Soc Clin Oncol, 2005)